Type II-activated macrophages suppress the development of experimental autoimmune encephalomyelitis

Immunology and Cell Biology

Volumn 87, Issue 3, 2009, Pages 235-240

  Tierney, Joanna B ^a   Kharkrang, Marie ^a   La Flamme, Anne Camille ^a  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

Author keywords

Autoimmunity; EAE; Fc receptors; Immune complexes; Macrophage; Macrophage activation

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; FC RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P40; LIGAND; LIPOPOLYSACCHARIDE; PD L1 PROTEIN; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNITY; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; INFLAMMATION; MACROPHAGE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; TREATMENT RESPONSE;

ANIMALS; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, CD40; ANTIGENS, CD80; DOWN-REGULATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GLYCOPROTEINS; IMMUNOLOGIC FACTORS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-12 SUBUNIT P40; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; MACROPHAGES; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; PEPTIDES; RECEPTORS, IGG;

MUS;

EID: 62849127355     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2008.99     Document Type: Article

References (27)

1. Goerdt S, Politz O, Schledzewski K, Birk R, Gratchev A, Guillot P et al. Alternative versus classical activation of macrophages. Pathobiology 1999; 67: 222-226.
2. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3: 23-35.
3. Anderson CF, Mosser DM. A novel phenotype for an activated macrophage: the type 2 activated macrophage. J Leukoc Biol 2002; 72: 101-106.
4. Sutterwala FS, Noel GJ, Clynes R, Mosser DM. Selective suppression of interleukin-12 induction after macrophage receptor ligation. J Exp Med 1997; 185: 1977-1985.
5. Anderson CF, Mosser DM. Cutting edge: biasing immune responses by directing antigen to macrophage Fc gamma receptors. J Immunol 2002; 168: 3697-3701.
6. La Flamme AC, Harvie M, McNeill A, Goldsack L, Tierney JB, Bäckström BT. Fc gamma receptor-ligating complexes improve the course of experimental autoimmune encephalomyelitis by enhancing basal Th2 responses. Immunol Cell Biol 2006; 84: 522-529.
7. Martiney JA, Rajan AJ, Charles PC, Cerami A, Ulrich PC, Macphail S et al. Prevention and treatment of experimental autoimmune encephalomyelitis by CNI-1493, a macrophage-deactivating agent. J Immunol 1998; 160: 5588-5595.
8. Tran EH, Hoekstra K, van Rooijen N, Dijkstra CD, Owens T. Immune invasion of the central nervous system parenchyma and experimental allergic encephalomyelitis, but not leukocyte extravasation from blood, are prevented in macrophage-depleted mice. J Immunol 1998; 161: 3767-3775.
9. Mosser DM. The many faces of macrophage activation. J Leukoc Biol 2003; 73: 209-212.
10. Girvin AM, Dal Canto MC, Rhee L, Salomon B, Sharpe A, Bluestone JA et al. A critical role for B7/CD28 costimulation in experimental autoimmune encephalomyelitis: a comparative study using costimulatory molecule-deficient mice and monoclonal antibody blockade. J Immunol 2000; 164: 136-143.
11. Girvin AM, Dal Canto MC, Miller SD. CD40/CD40L interaction is essential for the induction of EAE in the absence of CD28-mediated co-stimulation. J Autoimmun 2002; 18: 83-94.
12. Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci USA 2003; 100: 5336-5341.
13. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 1992; 176: 287-292.
14. Sutterwala FS, Noel GJ, Salgame P, Mosser DM. Reversal of proinflammatory responses by ligating the macrophage Fc gamma receptor type I. J Exp Med 1998; 188: 217-222.
15. Gerber JS, Mosser DM. Reversing lipopolysaccharide toxicity by ligating the macrophage Fc gamma receptors. J Immunol 2001; 166: 6861-6868.
16. Taylor PR, Martinez-Pomares L, Stacey M, Lin HH, Brown GD, Gordon S. Macrophage receptors and immune recognition. Annu Rev Immunol 2005; 23: 901-944.
17. Edwards JP, Zhang X, Frauwirth KA, Mosser DM. Biochemical and functional characterization of three activated macrophage populations. J Leukoc Biol 2006; 80: 1298-1307.
18. Latchman YE, Liang SC, Wu Y, Chernova T, Sobel RA, Klemm M et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci USA 2004; 101: 10691-10696.
19. MacDonald AS, Straw AD, Dalton NM, Pearce EJ. Cutting edge: Th2 response induction by dendritic cells: a role for CD40. J Immunol 2002; 168: 537-540.
20. Murugaiyan G, Martin S, Saha B. Levels of CD40 expression on dendritic cells dictate tumour growth or regression. Clin Exp Immunol 2007; 149: 194-202.
21. Miles SA, Conrad SM, Alves RG, Jeronimo SM, Mosser DM. A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J Exp Med 2005; 201: 747-754.
22. Weber MS, Prod'homme T, Youssef S, Dunn SE, Rundle CD, Lee L et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 2007; 13: 935-943.
23. Stern JN, Keskin DB, Zhang H, Lv H, Kato Z, Strominger JL. Amino acid copolymer-specific IL-10-secreting regulatory T cells that ameliorate autoimmune diseases in mice. Proc Natl Acad Sci USA 2008; 105: 5172-5176.
24. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008; 26: 513-533.
25. Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G et al. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 2008; 111: 715-722.
26. La Flamme AC, Ruddenklau K, Bäckström BT. Schistosomiasis decreases central nervous system inflammation and alters the progression of experimental autoimmune encephalomyelitis. Infect Immun 2003; 71: 4996-5004.
27. Crume KP, Miller JH, La Flamme AC. Peloruside A, an antimitotic agent, specifically decreases tumor necrosis factor-alpha production by lipopolysaccharide-stimulated murine macrophages. Exp Biol Med (Maywood) 2007; 232: 607-613.